These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
298 related articles for article (PubMed ID: 34028386)
1. Immunogenicity and Reactogenicity After SARS-CoV-2 mRNA Vaccination in Kidney Transplant Recipients Taking Belatacept. Ou MT; Boyarsky BJ; Chiang TPY; Bae S; Werbel WA; Avery RK; Tobian AAR; Massie AB; Segev DL; Garonzik-Wang JM Transplantation; 2021 Sep; 105(9):2119-2123. PubMed ID: 34028386 [TBL] [Abstract][Full Text] [Related]
2. SARS-CoV-2 anti-spike antibodies after a fourth dose of COVID-19 vaccine in adult solid-organ transplant recipients. Perrier Q; Lupo J; Gerster T; Augier C; Falque L; Rostaing L; Pelletier L; Bedouch P; Blanc M; Saint-Raymond C; Boignard A; Bonadona A; Noble J; Epaulard O Vaccine; 2022 Oct; 40(44):6404-6411. PubMed ID: 36184404 [TBL] [Abstract][Full Text] [Related]
3. Humoral Response after SARS-CoV-2 mRNA Vaccination in a Cohort of Hemodialysis Patients and Kidney Transplant Recipients. Danthu C; Hantz S; Dahlem A; Duval M; Ba B; Guibbert M; El Ouafi Z; Ponsard S; Berrahal I; Achard JM; Bocquentin F; Allot V; Rerolle JP; Alain S; Touré F J Am Soc Nephrol; 2021 Sep; 32(9):2153-2158. PubMed ID: 34135083 [TBL] [Abstract][Full Text] [Related]
4. Evidence of potent humoral immune activity in COVID-19-infected kidney transplant recipients. Hartzell S; Bin S; Benedetti C; Haverly M; Gallon L; Zaza G; Riella LV; Menon MC; Florman S; Rahman AH; Leech JM; Heeger PS; Cravedi P Am J Transplant; 2020 Nov; 20(11):3149-3161. PubMed ID: 32786152 [TBL] [Abstract][Full Text] [Related]
5. Weak antibody response to three doses of mRNA vaccine in kidney transplant recipients treated with belatacept. Chavarot N; Morel A; Leruez-Ville M; Vilain E; Divard G; Burger C; Serris A; Sberro-Soussan R; Martinez F; Amrouche L; Bererhi L; Lanternier F; Legendre C; Zuber J; Anglicheau D; Scemla A Am J Transplant; 2021 Dec; 21(12):4043-4051. PubMed ID: 34431207 [TBL] [Abstract][Full Text] [Related]
6. Increased Pretransplant Frequency of CD28 Cortes-Cerisuelo M; Laurie SJ; Mathews DV; Winterberg PD; Larsen CP; Adams AB; Ford ML Am J Transplant; 2017 Sep; 17(9):2350-2362. PubMed ID: 28502091 [TBL] [Abstract][Full Text] [Related]
7. Conversion From Calcineurin Inhibitors to Belatacept in HLA-sensitized Kidney Transplant Recipients With Low-level Donor-specific Antibodies. Ulloa CE; Anglicheau D; Snanoudj R; Scemla A; Martinez F; Timsit MO; Legendre C; Sberro-Soussan R Transplantation; 2019 Oct; 103(10):2150-2156. PubMed ID: 30720681 [TBL] [Abstract][Full Text] [Related]
8. Humoral and Cellular Immune Response to a Third Dose of SARS-CoV-2 Vaccine in Kidney Transplant Recipients Taking Belatacept. Mitchell J; Kim J; Alejo JL; Chiang TP; Karaba AH; Blankson JN; Aytenfisu TY; Chang A; Abedon AT; Avery RK; Tobian AA; Massie AB; Levan ML; Warren DS; Garonzik-Wang JM; Segev DL; Werbel WA Transplantation; 2022 May; 106(5):e264-e265. PubMed ID: 35289776 [No Abstract] [Full Text] [Related]
9. Comparison of SARS-CoV-2 Antibody Response 4 Weeks After Homologous vs Heterologous Third Vaccine Dose in Kidney Transplant Recipients: A Randomized Clinical Trial. Reindl-Schwaighofer R; Heinzel A; Mayrdorfer M; Jabbour R; Hofbauer TM; Merrelaar A; Eder M; Regele F; Doberer K; Spechtl P; Aschauer C; Koblischke M; Paschen C; Eskandary F; Hu K; Öhler B; Bhandal A; Kleibenböck S; Jagoditsch RI; Reiskopf B; Heger F; Bond G; Böhmig GA; Strassl R; Weseslindtner L; Indra A; Aberle JH; Binder M; Oberbauer R JAMA Intern Med; 2022 Feb; 182(2):165-171. PubMed ID: 34928302 [TBL] [Abstract][Full Text] [Related]
10. Humoral and cellular immune response and the safety of third SARS-CoV-2 mRNA vaccine with longer interval after the second vaccination in kidney transplant recipients. Takai S; Nishida H; Ito H; Fukuhara H; Nawano T; Narisawa T; Kanno H; Yagi M; Yamagishi A; Sakurai T; Naito S; Kato T; Morikane K; Tsuchiya N Front Immunol; 2022; 13():1050211. PubMed ID: 36532067 [TBL] [Abstract][Full Text] [Related]
11. Safety and Reactogenicity of 2 Doses of SARS-CoV-2 Vaccination in Solid Organ Transplant Recipients. Ou MT; Boyarsky BJ; Motter JD; Greenberg RS; Teles AT; Ruddy JA; Krach MR; Jain VS; Werbel WA; Avery RK; Massie AB; Segev DL; Garonzik-Wang JM Transplantation; 2021 Oct; 105(10):2170-2174. PubMed ID: 33859151 [TBL] [Abstract][Full Text] [Related]
12. Antibody response to SARS-CoV-2 mRNA vaccine among kidney transplant recipients: a prospective cohort study. Rozen-Zvi B; Yahav D; Agur T; Zingerman B; Ben-Zvi H; Atamna A; Tau N; Mashraki T; Nesher E; Rahamimov R Clin Microbiol Infect; 2021 Aug; 27(8):1173.e1-1173.e4. PubMed ID: 33957273 [TBL] [Abstract][Full Text] [Related]
13. Assessment of humoral and cellular immune responses to SARS CoV-2 vaccination (BNT162b2) in immunocompromised renal allograft recipients. Zhang R; Shin BH; Gadsden TM; Petrosyan A; Vo A; Ammerman N; Sethi S; Huang E; Peng A; Najjar R; Atienza J; Kim I; Jordan SC Transpl Infect Dis; 2022 Apr; 24(2):e13813. PubMed ID: 35202497 [TBL] [Abstract][Full Text] [Related]
14. Cellular and Humoral Immune Responses After 3 Doses of BNT162b2 mRNA SARS-CoV-2 Vaccine in Kidney Transplant. Stumpf J; Tonnus W; Paliege A; Rettig R; Steglich A; Gembardt F; Kessel F; Kröger H; Arndt P; Sradnick J; Frank K; Tonn T; Hugo C Transplantation; 2021 Nov; 105(11):e267-e269. PubMed ID: 34342963 [TBL] [Abstract][Full Text] [Related]